GenTraceDx for Clinicians
A Canadian National Pilot for Continuously Updating Precision Oncology
Developed with Canada’s Michael Smith Genome Sciences Centre and supported by Genome Canada and Genome BC, GenTraceDx is a living diagnostic platform designed to bring continuously updating clinical intelligence into real-world oncology care.
WHY THIS MATTERS
Why GenTraceDx
Precision oncology is advancing rapidly, yet many genomic reports remain static and quickly become outdated.
GenTraceDx is designed as a continuously updating clinical intelligence system, integrating genomic data with evolving clinical evidence to support therapy selection and trial identification over time.
This approach is being evaluated through a 500-patient national pilot across Canada.
GenTraceDx is designed as a continuously updating clinical intelligence system, integrating genomic data with evolving clinical evidence to support therapy selection and trial identification over time.
This approach is being evaluated through a 500-patient national pilot across Canada.
What This Means for Your Patients
- Identify therapeutic opportunities that may not be initially apparent
- Stay aligned with evolving clinical evidence, approvals, and guidelines
- Access RNA-informed insights beyond traditional panel-based testing
- Support treatment decisions with continuously updated clinical intelligence
WHAT THE PLATFORM DOES
GenTraceDx Clinical Intelligence Suite
A continuously updating clinical intelligence system designed for real-world oncology practice:
- Living Reports: Continuously updated genomic interpretations as clinical evidence evolves
- Real-Time Clinical Alerts: Notifications when new therapies, approvals, or evidence become relevant
- Therapy Identification: On-label, off-label, DIN, and Special Access Program (SAP) opportunities
- Trial Matching: Ongoing identification of relevant clinical trial options
- Multiomic Profiling: Tumour–normal whole exome sequencing and whole-transcriptome RNA analysis
- Tumour Board Support: Clinician-ready summaries for case review and discussion
How It Works
Step 1
Patient Enrollment
Patients are enrolled through participating institutions as part of the GenTraceDx national pilot.
Step 1
Step 2
Sample Collection & Analysis
Tumour and matched normal samples are analyzed using whole exome sequencing and whole-transcriptome RNA profiling.
Step 2
Step 3
Initial Report Delivery
Clinicians receive a comprehensive genomic report with initial therapeutic insights.
Step 3
Step 4
Continuous Reanalysis
GenTraceDx continuously integrates new clinical evidence and reinterprets patient-specific data over time.
Step 4
Step 5
Ongoing Updates
Clinicians receive real-time notifications when new therapies, approvals, or clinical trials become relevant.
Step 5
GenTraceDx National Pilot
GenTraceDx is being introduced through a 500-patient national pilot across Canada, supported by Genome Canada and Genome British Columbia and developed in collaboration with Canada’s Michael Smith Genome Sciences Centre. Participating clinicians will contribute to a national effort to evaluate and implement continuously updating precision oncology in clinical practice.
Pilot Objectives
- Evaluate the clinical utility of continuous genomic interpretation
- Integrate longitudinal clinical intelligence into real-world oncology workflows
- Expand access to comprehensive multiomic analysis in clinical settings
Who Can Participate
- Oncology centres
- Hospitals and academic institutions
- Licensed oncology specialists
Patient Selection
GenTraceDx may be considered for patients with:
- Advanced, refractory, or rare malignancies
- Unclear next-line treatment strategies
- Limited standard-of-care options or high unmet therapeutic need
- Potential eligibility for clinical trial participation
- Genomically complex or ambiguous tumour profiles
Appropriate Clinical Use
- At diagnosis, to inform treatment planning
- At disease progression, to identify additional therapeutic options
- Following treatment resistance, to evaluate clinical trials and off-label therapies
- In rare or complex cancers, where panel-based testing may be insufficient
Physician Portal Access
The GenTraceDx Physician Portal is available to credentialed clinical users enrolled in the GenTraceDx national pilot (Fall 2026). Pre-enrollment is open to physicians and institutions.
To participate:
- Submit a registration using the form below
- Complete enrollment and onboarding before the pilot begins
- Receive portal access prior to referring patients
Security & Compliance
- Restricted to credentialed clinical users
- Compliant with PHIPA and PIPEDA
- Encrypted storage and transmission of genomic and clinical data
- Continuous monitoring, access controls, and audit logging
Clinical Support
For platform or technical inquiries:
Secure messaging is also available within the platform for enrolled users.
Clinical Use Disclaimer
GenTraceDx is a clinical decision-support tool.
It does not replace professional judgment or institutional protocols. All treatment decisions remain the responsibility of the treating clinician.
HOW TO JOIN
Join the GenTraceDx National Pilot
Physicians and clinical sites interested in participating in the GenTraceDx national pilot are invited to pre-enrol. Our team will follow up with enrollment and onboarding details.
Physician Registration Form
Supported by Leading Institutions
GenTraceDx is being developed through a national collaboration:
